argenx is a global, commercial-stage biopharma company developing differentiated therapies for severe autoimmune diseases. Founded in 2008, it is headquartered in Amsterdam and listed on Nasdaq and Euronext Brussels under ARGX.
argenx reported $1.3B in Q1 2026 global product net sales (63% YoY growth). The FDA PDUFA target date for seronegative gMG is May 10, 2026. Positive ADAPT OCULUS results support an oMG label expansion. Pipeline milestones include myositis readout in Q3 2026 and MMN readout in Q4 2026.
Global orphan drug sales are forecast to reach $409 billion by 2032, representing one-fifth of prescription drug sales, with Johnson & Johnson and Argenx leading the market amid regulatory uncertainty.
Novartis has signed a research partnership and licensing agreement with Unnatural Products valued at up to $1.8 billion to develop macrocyclic peptide therapeutics targeting cardiovascular diseases using AI-driven drug discovery.
Unnatural Products entered a research collaboration and licensing agreement with Novartis worth up to $1.8 billion to develop orally-delivered macrocyclic peptide therapeutics for an undisclosed cardiovascular program.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07773727 |
A Study to Evaluate the Effect of ARGX-121 on the Change in Proteinuria in Adult Participants With IgAN |
NOT_YET_RECRUITING | PHASE2 |
| NCT07760818 |
A Study to Assess Efficacy and Safety of Efgartigimod in Adults With Sjogren's Disease-associated Sensorimotor Polyneuropathy or Sensory Polyneuropathy (SERENITY) |
NOT_YET_RECRUITING | PHASE2 |
| NCT07746089 |
A Study to Assess Efficacy and Safety of Adimanebart in Adult and Pediatric Participants With DOK7-,MUSK-, AGRN-, or LRP4- Congenital Myasthenic Syndromes (CMS) |
NOT_YET_RECRUITING | PHASE3 |
| NCT07673627 |
ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis |
RECRUITING | PHASE2 |
| NCT07673601 |
A Study to Assess the Absolute Bioavailability and How Adimanebart SC Moves Through the Body in Healthy Adult Participants |
RECRUITING | PHASE1 |
| NCT07638566 |
A Study to Assess the Correct Dose, Safety and Efficacy of Empasiprubart in Adolescent Participants Aged 12 to Less Than 18 Years With Chronic Inflammatory Demyelinating Polyradiculoneuropathy |
NOT_YET_RECRUITING | PHASE2/PHASE3 |
| NCT07612020 |
A Study to Assess the Absolute Bioavailability of Empasiprubart SC Administered With an Autoinjector and the Pharmacokinetic Noninferiority of Empasiprubart SC Versus Intravenous (IV) in Healthy Adult Participants |
RECRUITING | PHASE1 |
| NCT07610564 |
A Study to Assess the Effect of Empasiprubart on Nerve Morphology by Ultrasound in Adults With Multifocal Motor Neuropathy |
RECRUITING | PHASE1 |
| NCT07596849 |
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease. |
RECRUITING | PHASE3 |
| NCT07595653 |
A Study to Evaluate the Impact of Efgartigimod on Overall Disease Experience of People Suffering From Generalized Myasthenia Gravis (gMG) in Italy |
RECRUITING |
